Three recent FDA warning letters, including one issued to publicly-traded Celularity, paint a helpful picture of where FDA oversight stands. They illustrate how the FDA’s classification of placental/amniotic products greatly depends on how a firm positions a product clinically. The marketing is key. Comparing these warnings three letters offers a useful window into current and […]
The post Celularity & 2 other perinatal biologics firms get FDA warnings appeared first on The Niche.